๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-04-30

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study (NCT07287137)

IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

๐Ÿ”ต Active, Not Recruiting Phase4 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Who can join: Review the eligibility criteria below.

Location: Walter Reed National Military Medical Center โ€” Bethesda, Maryland

Age range: 18 Years to 79 Years

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • Walter Reed National Military Medical Center โ€” Bethesda, Maryland

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All COVID -19 clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—